Physician profile
Todd E Vonderheide
NPI 1083720775
$4,998.37
in general payments reported to CMS, 2019-2025
35 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $220 · 2021: $517 · 2022: $765 · 2023: $926 · 2024: $693 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,006.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $745.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.81 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $359.01 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $293.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $246.74 | 2019-2025 | Vraylar, Qulipta |
| Pfizer INC. | $140.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $132.98 | 2019-2024 | |
| Dexcom, INC. | $129.07 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $125.86 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $116.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $107.85 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $107.46 | 2019-2021 | |
| Exact Sciences Corporation | $105.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $73.35 | 2019-2025 | Repatha, Otezla |
| Allergan, INC. | $72.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $69.77 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $52.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $40.13 | 2019-2020 | |
| Abbott Laboratories | $36.56 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $36.12 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $30.20 | 2019-2024 | Zoryve |
| Agile Therapeutics, INC. | $30.04 | 2022 | |
| Axsome Therapeutics, INC. | $29.19 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $21.83 | 2023 | |
| Esperion Therapeutics, INC. | $20.73 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.85 | 2022 | |
| Assertio Therapeutics, INC. | $15.76 | 2019 | |
| Sanofi Pasteur INC. | $13.63 | 2019 | |
| Mylan Specialty L.P. | $12.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.85 | 2022 | |
| Shire North American Group INC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Vonderheide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.